NEW YORK (Reuters) - AstraZeneca Plc (AZN.L), facing patent expirations on its top-selling medicines, sees room for more cost cuts in marketing, sales and other areas to shore up profits, its chief executive said on Wednesday.
NEW YORK (Reuters) - AstraZeneca Plc (AZN.L), facing patent expirations on its top-selling medicines, sees room for more cost cuts in marketing, sales and other areas to shore up profits, its chief executive said on Wednesday.
